Company intelligence / Profile preview

Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

Ownership: Private
Development stage: Phase 2

Overview

Shanghai Synergy Pharmaceutical Sciences has patented novel CCR4 antagonists with potential applications in cancer, autoimmune diseases, and inflammatory disorders. There are no publicly disclosed clinical results or late-stage programs as of the latest available information. The company appears focused on early-stage R&D with a portfolio centered around small molecule therapeutics targeting oncology and immunology indications.

Therapeutic areas: OncologyImmunology
Modalities: small moleculespotential for biologics based on patent activity, but primarily small molecules evidenced by CCR4 antagonist patents
Industry: Biotech

Drug pipeline

1 asset

hypidone

Partnerships

Zhejiang Huahai Pharmaceutical Group Co. Ltd.

Beyond the preview

Go deeper on Shanghai Synergy Pharmaceutical Sciences Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Synergy Pharmaceutical Sciences Co., Ltd..

Explore the full profile